Determine Long-Term Safety and Tolerability of Pregabalin in Patients With Anxiety Disorders.

Determine long-term safety and tolerability of pregabalin in patients with anxiety disorders.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Anxiety Neuroses Anxiety Disorders Mental Disorders

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Pfizer Investigational Site, A-1040 Wien, Austria

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Must have completed the double-blind portion of the preceding trial
Completed any protocol specified withdrawal phase and follow-up visits.

Exclusion criteria

Patient cannot participate if they experienced a serious adverse event or a nonserious, but medically significant adverse event during the preceding efficacy study that was judged to be related to the study medication.

Treatment and study plan

Pregabalin

Drug

Primary outcomes

Safety Tolerability

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

A 1-Year Open-Label Safety Extension Study of Pregabalin in Patients With Anxiety Disorders

Important dates

Study start: 2001
Study completion: 2006
First posted: Sep 8, 2005
Registry last updated: Jul 14, 2006

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed